Mitsui Chemicals, Inc., has been Debiopharm’s polymer supplier for Triptorelin’s sustained-release formula for more than 25 years (start of commercial supply of polymers in 1995).
For the first time, Debiopharm presented on Dec. 11th, 2020 its “2019 Best Supplier Award” to the Japanese company Mitsui Chemicals, Inc.
This award aims to recognize partners or vendors who are distinguished for their high-quality operations, product quality and logistics.
Mitsui has been Debiopharm’s supplier of the polymer technology behind the sustained release triptorelin formulations for more than 25 years, becoming one of the most valuable partners in the increasing success of Triptorelin worldwide.
The selection was made after 2019’s Review of Performances of all critical suppliers of Debiopharm’s manufacturing site in Martigny (Switzerland), and multiple Quality Audits ran by Marc Duval, Head of Suppliers Quality Management & Audits at Debiopharm.
Mitsui’s capacity to innovate and improve their quality over the years have been key elements guiding their nomination for the 2019 Best Supplier Award.
“It is a great honor for Mitsui to be awarded as the Best Supplier of the year 2019 by Debiopharm. We promise we will make our best efforts to maintain the stable supply and improve the quality”.
– Kazuhiko Togashi, General Manager, Personal Care Materials Division, Mitsui Chemicals, Inc.
Due to the Covid-19 pandemic, and restrictions for travels, this event has been delayed several times since March 2020, and the award was finally officially given to Mitsui during a videoconference on Dec. 11th, 2020, mains participants from Mitsui were Mr. Kazuhiko Togashi (General Manager, Personal Care Materials Division), Mr. Hiroki Ishibashi (Director, Medical Materials Dept., Personal Care Materials Division), Mr. Takayuki Hirai (Deputy Director, Medical Materials Dept., Personal Care Materials Division), Mr. Tomoyuki Natsuji (Manager, Medical Materials Dept., Personal Care Materials Division), Mr. Kimitaka Chida (Production Director), Mr. Hiroyuki Jitousyo (Production Manager), Mr. Gen Miyata (Quality Assurance Manager), Mr. Grégoire Boyer (Deputy General Manager, Mitsui Chemicals Europe GmbH), Mr. Alexander Weger (Sales & Marketing Manager, Mitsui Chemicals Europe GmbH), Mr. Yasuhito Abe (Account Manager, Mitsui Chemicals Europe GmbH) and from Debiopharm Mr. Cédric Sager (CEO), Mr. Thanh Liem Vu (Quality Assurance Director & QP), and Mr. Marc Duval (Head of Suppliers Quality Management & Audits).
“Debiopharm and Mitsui have been partnering for many years. Both companies have progressed together in terms of quality and operational excellence. We thank Mitsui for its continued commitment to Debiopharm”.
– Cédric Sager, CEO, Debiopharm Research & Manufacturing S.A.
Debiopharm is a world leader in polylactic-co-glycolic acid (PLGA)-based injectable, sustained-release technology. It has been used for an injectable controlled-release formulation of triptorelin – a gonadotropin releasing hormone (GnRH) agonist analogue. This mode of administration developed by Debiopharm in Martigny (Switzerland) relies on the active substance being “encapsulated” in a PLGA polymer to allow gradual dissolution and release of the substance in the patient’s body. Debiopharm has succeeded in producing three sustained-release formulations (1, 3 and 6 months). First registered in France in 1986, we continuously developed new formulations and new products (Decapeptyl®/Trelstar®/Pamorelin®/Triptodur®) that are currently marketed in more than 90 countries. We are market leader in many territories worldwide for the treatment of prostate cancer and endometriosis.